For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com
Daiichi Sankyo Completes Integration of Odawara Plants of Japan Supply Chain Subsidiaries
Tokyo, Japan (April 1, 2013) – DAIICHI SANKYOCOMPANY, LIMITED (hereafter, Daiichi Sankyo) today announced that it has completed the integration of the Odawara plants of its Japanese supply chain subsidiaries, DAIICHI SANKYO PROPHARMA CO., LTD. (hereafter, DSPP) and DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. (hereafter, DSCP) as previously announced in the October 1, 2012, news release entitled, “Daiichi Sankyo to Reorganize Japanese Supply Chain Subsidiaries and Integrate their Odawara Plants.”
- 1. Objective of integration
The two neighboring plants have been integrated in order to build a consistent system of
manufacturing everything from intermediates to API while utilizing scientific research capabilities to
enhance the manufacturing technology infrastructure and make Daiichi Sankyo structurally
competitive on a global level.
As of today, the DSPP Odawara plant has been split off and absorbed into DSCP, which will act as the
succeeding company through an Absorption-type Company Split as provided for in “The Companies
Act of Japan.” Consequently, the neighboring DSPP and DSCP Odawara plants have been integrated.
- 3. Post-integration overview for the new plant
Plant name: DAIICHI SANKYO CHEMICAL PHARMA CO., LTD., Odawara Plant
Location: 477, Takada, Odawara, Kanagawa, Japan
Area: 133,000 m2
Plant manager: Yoshinobu Ohshima
Employees: Approximately 250
Main products: API and intermediates for pharmaceuticals (olmesartan medoxomil, loxoprofen sodium, etc.)
For Reference
Overview of DSPP and DSCP (as of April 1, 2013)
DAIICHI SANKYO PROPHARMA CO., LTD.
Head office: 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, Japan
Plants: Akita, Onahama, Hiratsuka, Tatebayashi, Takatsuki
Capital: 100 million yen (100% owned by Daiichi Sankyo)
Representative: Tsutomu Shimizu, Representative Director & President
Sales: 78 billion yen (fiscal year ending in March 2012)
Employees: Approximately 1,430
Main businesses: Manufacture and contract manufacture of pharmaceuticals, OTC drugs, and
investigational drugs
DAIICHI SANKYO CHEMICAL PHARMA CO., LTD.
Head office: 4-4-8, Nishiyawata, Hiratsuka, Kanagawa, Japan
Plants: Hiratsuka, Odawara
Capital: 50 million yen (100% owned by Daiichi Sankyo)
Representative: Akihiko Miyadera, Representative Director & President
Sales: 9.9 billion yen (fiscal year ending in March 2012)
Employees: Approximately 480
Main businesses: Manufacture and contract manufacture of API and intermediates for pharmaceuticals
End